Abstract: Provided are a method for preparing a polyetherketoneketone and a polyetherketoneketone prepared thereby, wherein, at the time of a polymerization reaction, nitrogen gas is blown into a liquid reaction medium while stirring, thereby quickly removing hydrochloric acid, which is a by-product generated during the reaction, and preventing aggregation of resin particles, thus suppressing the generation of scales.

Abstract: Disclosed is a fan-out buffer which includes a first channel that includes a first delay circuit adjusting a first delay time of a calibration test signal depending on a first delay control signal, a second channel that includes a second delay circuit adjusting a second delay time of the calibration test signal depending on a second delay control signal, a first edge-to-pulse converter that detects a first edge included in a first time domain reflectometry (TDR) waveform of an output terminal of the first channel and generates a first start pulse signal including a first pulse, a second edge-to-pulse converter that generates a second start pulse signal including a second pulse, a stop pulse signal generator that generates a stop pulse signal including a first stop pulse, and a first delay control signal generator that calculates a phase difference generates the first delay control signal.

Abstract: An infusion flow regulator includes: a main body having an inlet through which fluid is introduced and an outlet through which the fluid is discharged; and a rotary dial rotatably coupled to the main body, with a sealing member interposed therebetween, so as to regulate a flow rate of the fluid, in which the rotary dial includes a regulating flow path having a shape of a recessed groove in cross section with a first width and a first height, and the regulating flow path includes a first region in which the first width is constant and the first height is decreased, and a second region in which both the first width and the first height are decreased. By the aforementioned configuration, the infusion flow regulator for the fluid can accurately regulate the flow rate even in a region where the flow rate of the fluid is very small.

Abstract: The disclosure includes a first upper rail coupled to a first lower rail so as to be movable in the forward-backward direction, a second upper rail coupled to a second lower rail, which is disposed parallel to the first lower rail, so as to be movable in the forward-backward direction, drive motors respectively provided at the first upper rail and the second upper rail, a first rotation guide coupled to the first upper rail and provided with a first gear having a plurality of gear teeth, a second rotation guide coupled to the second upper rail and provided with a first gear having a plurality of gear teeth, and a seat cushion provided with second gears engaged with the first gears and configured to rotate when the first upper rail and the second upper rail move in opposite directions.

Abstract: The present disclosure relates to a vehicle rear seat including: a center seat; and side seats located on the left and right of the center seat, wherein, the center seat is capable of protruding by moving the center seat forward with respect to the side seats, and in the state in which the center seat protrudes forward, it is possible to increase an inter-passenger distance so that physical contact between the passenger of the center seat and the passenger of each of the side seats can be prevented as much as possible.

Abstract: An optical sensor includes a substrate, a photoelectric element disposed on the substrate and that includes a first electrode, an intermediate layer disposed on the first electrode, and a second electrode disposed on the intermediate layer, a barrier layer disposed on the second electrode, an insulating layer that covers the photoelectric element and the barrier layer, and a bias electrode disposed on the insulating layer and electrically connected to the second electrode. The barrier layer is spaced apart from the first electrode.

Abstract: A multilayer electronic component includes a body including a plurality of dielectric layers, side margin portions disposed on the body, and external electrodes disposed on the body. The reliability of the multilayer electronic component is improved by controlling the contents of Si for each position of the dielectric layer and the side margin portion.

Abstract: The present invention relates to a composition for preventing or treating cancer, containing a novel trifluoromethyl phenyl pyrazole derivative as an active ingredient, and, more specifically, to a composition for preventing, alleviating or treating cancer and a radiosensitizer composition for treating cancer with radiotherapy, which contain, as an active ingredient, a novel sulfonamide derivative including N,N-dimethyl-N?-(3-(1-(4-(trifluoromethyl)phenyl)-1H-pyrazol-4-yl)phenyl)azanesulfonamide. Novel sulfonamide derivatives according to the present invention have an excellent apoptotic effect on cancer cells, and thus are usable as an effective anti-cancer agent, and reduce the radioresistance of cancer cells, and thus can be used as a radiosensitizer composition during cancer treatment.

Abstract: The present disclosure is the first to identify a host cell protein and its function with which MPT63 and MPT64, secreted antigens of Mycobacterium tuberculosis, interact, and to construct a recombinant MPT protein including each domain of MPT63 and MPT64 interacting with the host cell protein, and the recombinant MPT protein may be applied to a use for the prevention and treatment of tuberculosis by confirming that the recombinant MPT protein targets the Mycobacterium tuberculosis-infected macrophages and increases the ROS level and inflammatory cytokine expression in macrophages, thereby inducing the death of Mycobacterium tuberculosis. And MPT protein of the present disclosure can improve the vaccine effect by the BCG vaccine so that it can be used as a tuberculosis vaccine and/or vaccine adjuvant either alone or together with known tuberculosis vaccines.

Abstract: The present invention relates to a novel Toxoplasma gondii GRA8-derived recombinant peptide, and a pharmaceutical composition and functional food for preventing or treating cancer, which includes the same as an active ingredient. The Toxoplasma gondii GRA8-derived recombinant peptide according to the present invention is a novel recombinant peptide in which a specific mitochondrial targeting sequence and an ATP5A1/SIRT3 sequence of GRA8 are conjugated to an acidity-triggered rational membrane (ATRAM), and has considerably improved efficacy in which an inhibitory concentration 50 (IC50) is improved up to 200-fold (in vitro) or 500-fold (in vivo), compared with a conventional GRA8-derived peptide (rGRA8). In addition, since the peptide treatment shows a notably distinct therapeutic effect in mouse models with cancer, the peptide may be effectively used in a pharmaceutical composition or functional food for preventing or treating cancer.

Abstract: The present invention relates to a pharmaceutical composition and a health functional food composition for preventing, alleviating or treating inflammatory diseases, including Toxoplasma gondii GRA9 protein or a gene encoding the protein as an active ingredient. The present inventors have identified the C-terminal region essential for the NLRP3-mediated mechanism of action and function of Toxoplasma gondii GRA9 in macrophages, which are host immune cells and confirmed the substantial anti-inflammatory and antibacterial effects and the antiseptic effect in vivo. Accordingly, Toxoplasma gondii GRA9 protein or a gene encoding the protein is expected to be usefully utilized in the field of prevention or treatment of inflammatory diseases caused by an abnormal NLRP3-mediated inflammatory response, including sepsis.

Abstract: A coating composition includes a compound of Chemical Formula 1: wherein the groups are described herein.

Abstract: An organic light emitting display device includes a display panel including a plurality of pixels each including an organic light emitting diode, a gate driver configured to supply a gate driving signal to each of the pixels, a data driver configured to supply a data voltage to each of the pixels, a multiplexer being switched in response to an external control signal to output any one of the data voltage and a voltage supplied from a separate power supply line, and a timing controller configured to control the multiplexer to transfer the data voltage to a data line of each of the pixels in a refresh period in a low-speed driving mode and transfer the voltage from the separate power supply line to the data line of each of the pixels for at least one anode reset period in a hold period in the low-speed driving mode.

Abstract: The present disclosure relates to a pixel circuit and a display device using the same. The pixel circuit includes a first switch element configured to connect a first node to a third node in a sampling step, a second switch element configured to supply a data voltage to a second node in the sampling step, a third switch element configured to supply a pixel driving voltage to the second node in a emission step after the sampling step, a fourth switch element configured to connect the third node to an anode of a light-emitting element in the emission step, a first capacitor connected to the first node, a second capacitor connected between the third node and the anode of the light-emitting element, and a third capacitor connected between the anode and the cathode of the light-emitting element.

Abstract: The present disclosure relates to a pixel circuit and a display device using the same. The pixel circuit includes a first switch element configured to connect a first node to a third node in a sampling step, a second switch element configured to supply a data voltage to a second node in the sampling step, a third switch element configured to supply a pixel driving voltage to the second node in a emission step after the sampling step, a fourth switch element configured to connect the third node to an anode of a light-emitting element in the emission step, a first capacitor connected to the first node, a second capacitor connected between the third node and the anode of the light-emitting element, and a third capacitor connected between the anode and the cathode of the light-emitting element.

Abstract: There is provided a scaffold for bone regeneration which is adapted to be implanted at a bone defect site of a bone. The scaffold comprises a main support member configured to be fixed to the bone, and a load supporting unit configured to be installed in the bone defect site of the bone to selectively bear a load applied to the bone. The load supporting unit includes one or two supporting pieces to be installed in the bone defect site of the bone to selectively bear a load applied to the bone. The supporting piece has at one end portion a contact portion to be brought into contact with and fixed to a compact bone in the bone defect site of the bone. The other end portion of the supporting piece is selectively coupled to the main support member.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating cancer, a radiosensitizer composition for treating cancer, and a health functional food for preventing or improving cancer, which comprise N-1H-benzimidazol-2-yl-3-(1H-pyrrol-1-yl) benzamide, a derivative thereof, or a pharmaceutically acceptable salt thereof as an active ingredient. The pharmaceutical composition comprising N-1H-benzimidazol-2-yl-3-(1H-pyrrol-1-yl) benzamide or a derivative thereof as an active ingredient according to the present invention arrests the mitosis of cancer cells to prevent proliferation and at the same time, to exhibit low toxicity in normal cell lines and induce apoptosis only in cancer cell lines, so it can be used as an effective anticancer agent. In addition, the N-1H-benzimidazol-2-yl-3-(1H-pyrrol-1-yl) benzamide of the present invention can increase the sensitivity of the treated cancer cells to radiation, so it can be used as a radiosensitizer composition for cancer treatment.

Abstract: An organic light emitting display device includes a display panel including a plurality of pixels each including an organic light emitting diode, a gate driver configured to supply a gate driving signal to each of the pixels, a data driver configured to supply a data voltage to each of the pixels, a multiplexer being switched in response to an external control signal to output any one of the data voltage and a voltage supplied from a separate power supply line, and a timing controller configured to control the multiplexer to transfer the data voltage to a data line of each of the pixels in a refresh period in a low-speed driving mode and transfer the voltage from the separate power supply line to the data line of each of the pixels for at least one anode reset period in a hold period in the low-speed driving mode.

Abstract: The present invention relates to a novel Toxoplasma gondii GRA8-derived recombinant peptide, and a pharmaceutical composition and functional food for preventing or treating cancer, which includes the same as an active ingredient. The Toxoplasma gondii GRA8-derived recombinant peptide according to the present invention is a novel recombinant peptide in which a specific mitochondrial targeting sequence and an ATP5A1/SIRT3 sequence of GRA8 are conjugated to an acidity-triggered rational membrane (ATRAM), and has considerably improved efficacy in which an inhibitory concentration 50 (IC50) is improved up to 200-fold (in vitro) or 500-fold (in vivo), compared with a conventional GRA8-derived peptide (rGRA8). In addition, since the peptide treatment shows a notably distinct therapeutic effect in mouse models with cancer, the peptide may be effectively used in a pharmaceutical composition or functional food for preventing or treating cancer.